Abstract
Greece is a country with limited spread of SARS-CoV-2 and cumulative infection attack rate of 0.12% (95%CI 0.06%-0.26%). Health care workers (HCWs) are a well-recognized risk group for COVID-19. The study aimed to estimate the seroprevalence of antibodies to SARS-CoV-2 in two hospitals and assess potential risk factors. Hospital-1 was involved in the care of COVID-19 patients while hospital-2 was not. A validated, rapid, IgM/IgG antibody point-of care test was used. 1,495 individuals consented to participate (response rate 77%). The anti-SARS-CoV-2 weighted prevalence was 1.07% (95%CI 0.37-1.78) overall and 0.44% (95%CI 0.12-1.13) and 2.4% (95%CI 0.51-8.19) in hospital-1 and hospital-2, respectively. The overall, hospital-1, and hospital-2 seroprevalence was 9, 3 and 20 times higher than the estimated infection attack rate in general population, respectively. Suboptimal use of personal protective equipment was noted in both hospitals. These data have implications for the preparedness of a second wave of COVID-19 epidemic.
Competing Interest Statement
The study was funded by research grant from Gilead Sciences
Funding Statement
The study was funded by research grant from Gilead Sciences
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Ethics and Scientific Boards of Laiko General Hospital, Athens, Greece and the Onassis Cardiac Surgery Center, Athens, Greece
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data will be available at the Pergamos database of the National and Kapodistrian University of Athens, upon acceptance of the article by a journal
